Brokerages Set Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Price Target at $32.67

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) has earned a consensus rating of “Buy” from the five analysts that are covering the company, Marketbeat.com reports. One research analyst has rated the stock with a hold rating, three have issued a buy rating and one has given a strong buy rating to the company. The average 12 month target price among brokerages that have covered the stock in the last year is $34.00.

A number of equities analysts recently weighed in on CPRX shares. Wall Street Zen raised Catalyst Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Sunday, November 16th. Oppenheimer reaffirmed an “outperform” rating and set a $33.00 target price on shares of Catalyst Pharmaceuticals in a research note on Friday, November 7th. Citigroup lifted their price target on shares of Catalyst Pharmaceuticals from $33.00 to $35.00 and gave the company a “buy” rating in a research note on Tuesday. Finally, Weiss Ratings reissued a “buy (b-)” rating on shares of Catalyst Pharmaceuticals in a report on Monday, December 29th.

Insider Buying and Selling at Catalyst Pharmaceuticals

In related news, Director Molly Harper sold 26,746 shares of the firm’s stock in a transaction dated Friday, December 12th. The shares were sold at an average price of $23.25, for a total value of $621,844.50. Following the transaction, the director directly owned 2,360 shares of the company’s stock, valued at approximately $54,870. This trade represents a 91.89% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. 10.40% of the stock is currently owned by company insiders.

Institutional Trading of Catalyst Pharmaceuticals

A number of institutional investors have recently made changes to their positions in the company. Federated Hermes Inc. boosted its position in Catalyst Pharmaceuticals by 52.8% during the third quarter. Federated Hermes Inc. now owns 389,289 shares of the biopharmaceutical company’s stock worth $7,669,000 after acquiring an additional 134,509 shares during the last quarter. Y Intercept Hong Kong Ltd raised its holdings in Catalyst Pharmaceuticals by 1,216.5% in the 3rd quarter. Y Intercept Hong Kong Ltd now owns 165,496 shares of the biopharmaceutical company’s stock valued at $3,260,000 after acquiring an additional 152,925 shares during the last quarter. Exchange Traded Concepts LLC lifted its stake in Catalyst Pharmaceuticals by 3,559.0% in the 3rd quarter. Exchange Traded Concepts LLC now owns 62,971 shares of the biopharmaceutical company’s stock worth $1,241,000 after purchasing an additional 61,250 shares in the last quarter. SG Americas Securities LLC boosted its holdings in shares of Catalyst Pharmaceuticals by 957.5% during the 3rd quarter. SG Americas Securities LLC now owns 83,690 shares of the biopharmaceutical company’s stock worth $1,649,000 after purchasing an additional 75,776 shares during the last quarter. Finally, Cresset Asset Management LLC grew its position in shares of Catalyst Pharmaceuticals by 588.1% in the second quarter. Cresset Asset Management LLC now owns 87,418 shares of the biopharmaceutical company’s stock valued at $1,897,000 after purchasing an additional 74,713 shares in the last quarter. 79.22% of the stock is owned by institutional investors and hedge funds.

Catalyst Pharmaceuticals Stock Performance

CPRX opened at $24.69 on Monday. The company has a fifty day moving average of $23.86 and a two-hundred day moving average of $22.30. The stock has a market capitalization of $3.02 billion, a price-to-earnings ratio of 14.61, a PEG ratio of 0.71 and a beta of 0.75. Catalyst Pharmaceuticals has a fifty-two week low of $19.05 and a fifty-two week high of $26.58.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapies for patients living with rare neuromuscular, neurological and metabolic diseases. The company’s mission centers on delivering safe and effective treatments that address unmet medical needs in small patient populations.

The company’s lead product is Firdapse® (amifampridine phosphate), a treatment approved by the U.S. Food and Drug Administration for adults with Lambert-Eaton Myasthenic Syndrome (LEMS).